.
MergerLinks Header Logo

New Deal


Announced

The Carlyle Group to acquire a majority stake in SeQuent Scientific for $210m.

Financials

Edit Data
Transaction Value£170m
Consideration TypeCash
Capital Owned-
Capital Bid For74%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pharmaceuticals

Pending

Majority

Public

India

Private Equity

pharmaceutical company

Acquisition

Single Bidder

Friendly

Tender Offer

Cross Border

Synopsis

Edit

The Carlyle Group agreed to acquire a majority stake in SeQuent Scientific, an integrated pharmaceutical company, for $210m. "SeQuent emerged as India’s leading animal healthcare company within six years, completing phase one of SeQuent’s growth journey. On behalf of the entire management team, I would like to thank Mr. Arun Kumar for his vision and support in building a global animal healthcare company. We look forward to a new phase of development, where we together with Carlyle will work to grow the company into one of the top global animal healthcare companies," Manish Gupta, SeQuent CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US